Introduction

Two functionally distinct CD4
+ T cell subsets have been identified: the CD45RA and CD45RO isoforms, where CD4
+ cells represent a subset of 'naive' T cells that may differentiate into CD4
+ 'memory' cells after appropriate antigenic stimulation.
1-4 CD4 + T cells switch from CD45RA
+ to CD45RO + through a CD45RA bright /CD45RO bright stage, and gradually lose CD45RA remaining CD45RO positive. 5, 6 Both subsets differently express adhesion molecules, and after in vitro and in vivo stimulation, display a distinct pattern of lymphokine production and different functional characteristics. [7] [8] [9] In fact, CD4 + /CD45RO + cells are able to secrete interleukin 4 (IL-4), interleukin 10 (IL-10) and interferon ␥ (IFN-␥) and provide B cell help, while CD4 + /CD45RA + cells produce interleukin 2 (IL-2). [10] [11] [12] The occurrence of phenotypic and functional abnormalities in T and NK cell compartments has been frequently documented in hairy cell leukemia (HCL) patients with active disease. 13, 14 In addition, there is a single observation reporting a significant reduction in the proportion and absolute number of CD4 + lymphocytes bearing the CD45RO antigen, suggesting that this alteration could be responsible for frequent infections in these patients. 15 In recent years, 2-chlorodeoxydenosine (2-CdA), a derivative nucleoside, has been successfully employed in HCL patients leading to very high and persistent complete remission (CR) rates. [16] [17] [18] However, together with very impressive results, this agent often induces myelosuppression as well as a remarkable and long lasting reduction of CD4 lymphocytes, leading to a not negligible increase of infectious complications. [18] [19] [20] [21] These findings prompted us to elucidate better the toxic effect of 2-CdA on the CD4 + T cell compartments by evaluating the CD45RA and CD45RO expression on CD4 + T cells in HCL patients at the onset of the disease and after 2-CdA treatment.
Patients and methods
Two different series of HCL patients, 19 at the onset of the disease and 19 previously treated with 2-CdA, entered the study. Thirty-one were males and seven were females with a median age of 56 years (range 36-75). 2-CdA (Janssen-Cilag) was administered in a single course, at a daily dose of 0.1 mg/kg c.i. for 7 days, as first line of therapy in 9/19 patients, while 10/19 patients were previously treated with ␣-interferon (␣-IFN). At the time of immunophenotypic analysis all HCL-treated patients were still in CR.
Immunophenotypic studies
Blood samples were obtained from all 38 HCL patients and 15 healthy individuals as normal control after informed consent. Since immunophenotypic profile of T lymphocytes was not modified by cryopreservation with DMSO, immunological studies were performed on fresh or cryopreserved cells after testing for viability with propidium iodide staining and analysis was carried out only if viable cells were Ͼ90%. In patients treated with 2-CdA the analysis was performed 37-62 months (median 54 months) by the end of therapy. Immunophenotypic characterization of T lymphoid subpopulations was assessed on peripheral blood mononuclear cells (PBMC), obtained by Lymphoprep (Nyegaard, Oslo, Norway) gradients, using a direct immunofluoresecence technique by flow cytometry (FACScan and FACScalibur; Becton Dickinson, San Jose, CA, USA) with a panel of monoclonal antibodies (MoAbs): CD3, CD4, CD8, CD16, CD56, CD57 or specific isotype controls phycoerythrin (PE) or fluorescein (FITC) conjugated (Becton Dickinson). Expression of CD45RA and CD45RO on CD4 + T cells was performed by three-color staining using the 4KB5 (CD45RO) FITC-conjugated, UCHL1 (CD45RA) PE-conjugated (Dako A/S, Glostrup, Denmark) and 
Statistical analysis
The Wilcoxon non-parametric test was used for statistical analysis.
Results
The proportion and absolute number of peripheral blood T cells and CD4 subsets in both groups of HCL patients and in normal controls are shown in Table 1 .
The 19 HCL untreated patients had a mean proportion of CD4 + /CD45RA
+ and CD4 + /CD45RO + T cell subsets similar to that recorded in normal controls (57 ± 14% vs 65 ± 7% and 47 ± 15% vs 42 ± 12%, respectively) ( Table 1 and Figure 1 
/CD45RO
+ T cells was higher than in untreated HCL patients and in normal controls (62 ± 16% vs 47 ± 15%, P = 0.08 and 62 ± 16% vs 42 ± 12%, P = 0.02, respectively), although the absolute number of this subset of cells resulted lower than that in untreated patients and in normal controls. Inadequate reconstitution of CD4 + T lymphocytes may be responsible for severe complications in patients undergoing intensive chemotherapy, or allogeneic bone marrow transplantation (alloBMT), as well as in patients with human immunodeficiency virus infection, or with hematological malignancies. 22, 23 It has been observed that after a T celldepleted alloBMT in pediatric patients the CD4 + T cell regeneration is age-correlated. 24 In children, in fact, CD4 + T cell regeneration after transplantation is thymus-dependent, resulting in a rapid appearance of CD4
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+ cells ('naive' phenotype) with concomitant thymus enlargement, while in adults CD4
+ T cell reconstitution is slower and occurs in a thymus-independent pathway with CD4 + T cells exclusively expressing CD45RO ('memory' phenotype). 23, 24 Abnormalities in T cell and NK cell compartments have often been documented in HCL patients 13, 14 at diagnosis. More recently, the introduction of nucleoside analogs, such as deoxycoformicin (DCF) and 2-CdA in the treatment of HCL patients, along with very impressive clinical and hematological results, produces severe neutropenia and long-lasting CD4 lymphocytopenia. [16] [17] [18] [19] [20] [21] 25 CD8-positive T cell subpopulation and B cells seem less affected by these agents, while patients who had been previously splenectomized tend to recover the T cell subpopulations earlier. 25 More recently, a further impairment has been documented within 'naive' and 'memory' CD4 cells with a reduction in the proportion and absolute number of CD4/CD45RO persisting for a long time even after remission, and attributed to 'unknown' factors that would hamper maturation of T helper cells. 15 On the basis of these findings, we investigated the toxic effect of 2-CdA on CD4
+ T cell subpopulations in HCL patients at diagnosis and in CR after therapy with this agent. Unlike previously published results, 15 in our study we demonstrated that both the proportion and the absolute number of CD4 + /CD45RA
+ and CD4 + /CD45RO + cells were similar in HCL patients at diagnosis with active disease and in normal controls. On the contrary, still 3-5 years after the administration of 2-CdA, together with a remarkable significant reduction of CD4 + T cells, we documented a significant and persistent reduction both in the proportion and in the absolute number of CD4 Similar results showing different sensitivity to chemotherapeutic agents in T cell subsets have also been reported in breast cancer patients in the first year post-chemotherapy. In these patients a 95% reduction in the proportion of CD4 + /CD45RA + 'naive' cells and a recovery of these cells to pretreatment values only 18 months after the end of treatment has been documented. 23 In conclusion, our data suggest that 2-CdA therapy results in a profound reduction of CD4 T cells, and in particular of the CD4 + /CD45RA
+ subset, lasting for even 5 years after treatment in HCL patients. This is likely due to 2-CdA treatment since patients previously treated only with IFN-␣ show normal RA/RO ratios (data not shown). However, it is conceivable that patients treated with 2-CdA, although showing a slow CD4
+ T cells recovery, may not be at high risk of severe infectious complications because they still maintain sufficient numbers of CD4 + /CD45RO + T cells.
